SCHEMBL9507670

SCHEMBL9507670

Cc1ccc2c(c1)Oc1ccccc1S2

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
KMT2A Q03164 2/20 0.38
ATM Q13315 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 1/20 0.35
GPR84 Q9NQS5 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
CYP2A6 P11509 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
BCHE P06276 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38661805 0.90 MAPT (0.36) LMNAKMT2AATMKDM4EMEN1
SCHEMBL9927340 0.90 MAPT (0.36) LMNAKMT2AATMKDM4EMEN1
SCHEMBL13203013 0.89 KMT2A (0.41) LMNAKMT2AATMKDM4EMEN1
SCHEMBL1610442 0.86 MAPT (0.46) LMNAKMT2AATMKDM4EMEN1
SCHEMBL19155781 0.86 DRD2 (0.41) LMNAHPGDBCHE
Phenoxathiine SCHEMBL28331949 0.82 LMNA (0.48) LMNAKMT2AATMKDM4EMEN1
Phenoxathiine SCHEMBL7922 0.81 MAOA (0.42) KMT2AATMMEN1MAPTTDP1
Phenoxathiine SCHEMBL29396568 0.81 MAOA (0.42) KMT2AATMMEN1MAPTTDP1
Phenoxathiine SCHEMBL29373698 0.81 MAOA (0.42) KMT2AATMMEN1MAPTTDP1
SCHEMBL18199790 0.79 AHR (0.47) LMNAALDH1A1HTTMAPTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4243782-A POLYMERIZATION CATALYSTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1981-01-06 US claimed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
US-11217758-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2022-01-04 US disclosed
US-20200321538-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2020-10-08 US disclosed
US-10797246-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2020-10-06 US disclosed
US-10727418-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2020-07-28 US disclosed
US-20170170405-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-15 US disclosed
US-9634260-B2 Method for preparing conjugated compound having phenoxathiin and electron donating group of conjugated aromatic unit, and OLED device having the conjugated compound SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2017-04-25 US disclosed
US-20170054083-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-02-23 US disclosed
US-20160322584-A1 CONJUGATED COMPOUND HAVING PHENOXATHIINL, METHOD FOR PREPARING THE SAME AND OLED DEVICE SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2016-11-03 US disclosed
US-20070089248-A1 Cosmetic formulations comprising diketo-pyrrolo pyrrole pigments WALLQUIST OLOF 2007-04-26 US disclosed
US-20070089248-A1 Cosmetic formulations comprising diketo-pyrrolo pyrrole pigments WALLQUIST OLOF 2007-04-26 US disclosed
EP-0399293-B1 PROCESS FOR PREPARING 2-CHLORO-4-NITRO-ALKYLBENZENE BAYER AG (DE) 1993-09-01 EP disclosed
US-5095157-A Friedel-crafts catalyst BAYER AKTIENGESELLSCHAFT (DE) 1992-03-10 US disclosed
EP-0399293-A1 Process for preparing 2-chloro-4-nitro-alkylbenzene BAYER AG (DE) 1990-11-28 EP disclosed
EP-0173222-B1 PROCESS FOR THE NUCLEAR CHLORINATION OF TOLUENE HOECHST AKTIENGESELLSCHAFT (DE) 1988-03-09 EP disclosed
US-4647709-A Process for ring-chlorinating toluene HOECHST AKTIENGESELLSCHAFT (DE) 1987-03-03 US disclosed
EP-0173222-A1 Process for the nuclear chlorination of toluene HOECHST AKTIENGESELLSCHAFT (DE) 1986-03-05 EP disclosed
US-4243782-A POLYMERIZATION CATALYSTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1981-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160322584-A1 CONJUGATED COMPOUND HAVING PHENOXATHIINL, METHOD FOR PREPARING THE SAME AND OLED DEVICE AOC2, OCIAD2, AOX1 LMNA 2671/4885KMT2A 1268/4885ATM 3404/4885
US-20070089248-A1 Cosmetic formulations comprising diketo-pyrrolo pyrrole pigments TYR, LAGE3, KRT18 LMNA 2598/4885KMT2A 838/4885ATM 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.